Allurion Earnings Reports

The company reported Q4 2024 revenue of $5.6 million, down from $8.2 million in the prior year. Gross margin declined to 45% due to lower production volumes and inventory adjustments. Operating expenses were reduced significantly, contributing to a lower net loss compared to previous quarters.

Allurion Technologies reported a revenue of $5.4 million for Q3 2024, which includes a $1.2 million reduction for product recalled from France. The company is updating its full-year 2024 revenue guidance to between $30 million and $35 million and expects growth in procedure volume to be flat year-over-year. A business restructuring plan is expected to reduce operating expenses by 50% in 2025 and achieve profitability by the end of 2025.

Allurion Technologies, Inc. announced its Q2 2024 financial results, highlighted by a sequential revenue increase of $2.4 million from Q1 2024, reaching $11.8 million, and a 12% year-over-year growth in procedure volume. The company's loss from operations decreased by 30% compared to the previous year, and they updated their full-year 2024 revenue guidance to between $40 million and $45 million.

Allurion Technologies, Inc. reported first quarter 2024 revenue of $9.4 million, a 14% increase from the fourth quarter of 2023. The company's cash burn was reduced to $8.4 million, and procedural volume increased by 12% year-over-year. They also launched the Virtual Care Suite (VCS) digital platform in the United States and closed a $48 million convertible senior secured note financing.

Allurion Technologies reported Q4 2023 revenue of $8.2 million, compared to $19.2 million for the same period in 2022. The company's cash and cash equivalents totaled $38 million as of December 31, 2023. They are reiterating the financial guidance it previously published for full year 2024.